国务院：300万医药代表全部登记备案！不得承担销售任务-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=1666641, encodeId=c03116666413c, content=<a href='/topic/show?id=df6a8e287d7' target=_blank style='color:#2F92EE;'>#药代#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87287, encryptionId=df6a8e287d7, topicName=药代)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bccf26064950, createdName=fengyqf, createdTime=Mon Feb 27 06:49:00 CST 2017, time=2017-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1687269, encodeId=4a8e168e269e3, content=<a href='/topic/show?id=df72966659b' target=_blank style='color:#2F92EE;'>#销售#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96665, encryptionId=df72966659b, topicName=销售)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bca28361924, createdName=1249862am81(暂无昵称), createdTime=Fri Nov 03 10:49:00 CST 2017, time=2017-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=175898, encodeId=7a2e1e5898bc, content=好文，顶一个, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9692001322, createdName=鼎臣咨询, createdTime=Mon Feb 13 11:33:29 CST 2017, time=2017-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1408823, encodeId=8bea1408823e5, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Sun Feb 12 07:49:00 CST 2017, time=2017-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1443574, encodeId=0d7d14435e489, content=<a href='/topic/show?id=eaf6352e26e' target=_blank style='color:#2F92EE;'>#医药代表#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35272, encryptionId=eaf6352e26e, topicName=医药代表)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKUnmV4MWxxicaHm4w2E4EPicofrVHWChQPKibnOtt8t8j7jYGkdKxNvF0KkC2sDXw04QS2GS2UUBSLg/132, createdBy=5cc15086507, createdName=ms9203727104890838, createdTime=Sun Feb 12 07:49:00 CST 2017, time=2017-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590897, encodeId=7b7c159089e63, content=<a href='/topic/show?id=f175424e6fe' target=_blank style='color:#2F92EE;'>#备案#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42476, encryptionId=f175424e6fe, topicName=备案)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=41f217885803, createdName=cenghis, createdTime=Sun Feb 12 07:49:00 CST 2017, time=2017-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=175605, encodeId=90f11e560557, content=能执行吗, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20170206/IMG589879E392F941842.jpg, createdBy=f4d469996, createdName=wangyunyb, createdTime=Sat Feb 11 16:38:37 CST 2017, time=2017-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=175566, encodeId=643c1e5566d6, content=真的吗？, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6d551998554, createdName=1e1c07bdm01(暂无匿称), createdTime=Sat Feb 11 11:33:30 CST 2017, time=2017-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=175550, encodeId=7f621e55508b, content=非常大的改革, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7LIiaRZTzJ3SEfiauCzTMPW7YvPPYLNJBXG9oh6Al1icq2VQQkIHWxqXehcicTS62YKJVBhxeth3wggw/0, createdBy=7ce01621306, createdName=天涯183, createdTime=Sat Feb 11 10:42:39 CST 2017, time=2017-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=175484, encodeId=87c81e5484a0, content=社会现象。, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2017/04/21/72142930668371951a41ef4ea4b233e6.jpg, createdBy=dcbc1715228, createdName=刘煜, createdTime=Sat Feb 11 06:51:37 CST 2017, time=2017-02-11, status=1, ipAttribution=)]

2017-02-27 fengyqf

#药代#

37 0

[GetPortalCommentsPageByObjectIdResponse(id=1666641, encodeId=c03116666413c, content=<a href='/topic/show?id=df6a8e287d7' target=_blank style='color:#2F92EE;'>#药代#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87287, encryptionId=df6a8e287d7, topicName=药代)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bccf26064950, createdName=fengyqf, createdTime=Mon Feb 27 06:49:00 CST 2017, time=2017-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1687269, encodeId=4a8e168e269e3, content=<a href='/topic/show?id=df72966659b' target=_blank style='color:#2F92EE;'>#销售#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96665, encryptionId=df72966659b, topicName=销售)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bca28361924, createdName=1249862am81(暂无昵称), createdTime=Fri Nov 03 10:49:00 CST 2017, time=2017-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=175898, encodeId=7a2e1e5898bc, content=好文，顶一个, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9692001322, createdName=鼎臣咨询, createdTime=Mon Feb 13 11:33:29 CST 2017, time=2017-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1408823, encodeId=8bea1408823e5, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Sun Feb 12 07:49:00 CST 2017, time=2017-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1443574, encodeId=0d7d14435e489, content=<a href='/topic/show?id=eaf6352e26e' target=_blank style='color:#2F92EE;'>#医药代表#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35272, encryptionId=eaf6352e26e, topicName=医药代表)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKUnmV4MWxxicaHm4w2E4EPicofrVHWChQPKibnOtt8t8j7jYGkdKxNvF0KkC2sDXw04QS2GS2UUBSLg/132, createdBy=5cc15086507, createdName=ms9203727104890838, createdTime=Sun Feb 12 07:49:00 CST 2017, time=2017-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590897, encodeId=7b7c159089e63, content=<a href='/topic/show?id=f175424e6fe' target=_blank style='color:#2F92EE;'>#备案#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42476, encryptionId=f175424e6fe, topicName=备案)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=41f217885803, createdName=cenghis, createdTime=Sun Feb 12 07:49:00 CST 2017, time=2017-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=175605, encodeId=90f11e560557, content=能执行吗, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20170206/IMG589879E392F941842.jpg, createdBy=f4d469996, createdName=wangyunyb, createdTime=Sat Feb 11 16:38:37 CST 2017, time=2017-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=175566, encodeId=643c1e5566d6, content=真的吗？, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6d551998554, createdName=1e1c07bdm01(暂无匿称), createdTime=Sat Feb 11 11:33:30 CST 2017, time=2017-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=175550, encodeId=7f621e55508b, content=非常大的改革, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7LIiaRZTzJ3SEfiauCzTMPW7YvPPYLNJBXG9oh6Al1icq2VQQkIHWxqXehcicTS62YKJVBhxeth3wggw/0, createdBy=7ce01621306, createdName=天涯183, createdTime=Sat Feb 11 10:42:39 CST 2017, time=2017-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=175484, encodeId=87c81e5484a0, content=社会现象。, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2017/04/21/72142930668371951a41ef4ea4b233e6.jpg, createdBy=dcbc1715228, createdName=刘煜, createdTime=Sat Feb 11 06:51:37 CST 2017, time=2017-02-11, status=1, ipAttribution=)]

2017-11-03 1249862am81(暂无昵称)

#销售#

34 0

[GetPortalCommentsPageByObjectIdResponse(id=1666641, encodeId=c03116666413c, content=<a href='/topic/show?id=df6a8e287d7' target=_blank style='color:#2F92EE;'>#药代#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87287, encryptionId=df6a8e287d7, topicName=药代)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bccf26064950, createdName=fengyqf, createdTime=Mon Feb 27 06:49:00 CST 2017, time=2017-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1687269, encodeId=4a8e168e269e3, content=<a href='/topic/show?id=df72966659b' target=_blank style='color:#2F92EE;'>#销售#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96665, encryptionId=df72966659b, topicName=销售)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bca28361924, createdName=1249862am81(暂无昵称), createdTime=Fri Nov 03 10:49:00 CST 2017, time=2017-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=175898, encodeId=7a2e1e5898bc, content=好文，顶一个, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9692001322, createdName=鼎臣咨询, createdTime=Mon Feb 13 11:33:29 CST 2017, time=2017-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1408823, encodeId=8bea1408823e5, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Sun Feb 12 07:49:00 CST 2017, time=2017-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1443574, encodeId=0d7d14435e489, content=<a href='/topic/show?id=eaf6352e26e' target=_blank style='color:#2F92EE;'>#医药代表#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35272, encryptionId=eaf6352e26e, topicName=医药代表)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKUnmV4MWxxicaHm4w2E4EPicofrVHWChQPKibnOtt8t8j7jYGkdKxNvF0KkC2sDXw04QS2GS2UUBSLg/132, createdBy=5cc15086507, createdName=ms9203727104890838, createdTime=Sun Feb 12 07:49:00 CST 2017, time=2017-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590897, encodeId=7b7c159089e63, content=<a href='/topic/show?id=f175424e6fe' target=_blank style='color:#2F92EE;'>#备案#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42476, encryptionId=f175424e6fe, topicName=备案)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=41f217885803, createdName=cenghis, createdTime=Sun Feb 12 07:49:00 CST 2017, time=2017-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=175605, encodeId=90f11e560557, content=能执行吗, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20170206/IMG589879E392F941842.jpg, createdBy=f4d469996, createdName=wangyunyb, createdTime=Sat Feb 11 16:38:37 CST 2017, time=2017-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=175566, encodeId=643c1e5566d6, content=真的吗？, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6d551998554, createdName=1e1c07bdm01(暂无匿称), createdTime=Sat Feb 11 11:33:30 CST 2017, time=2017-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=175550, encodeId=7f621e55508b, content=非常大的改革, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7LIiaRZTzJ3SEfiauCzTMPW7YvPPYLNJBXG9oh6Al1icq2VQQkIHWxqXehcicTS62YKJVBhxeth3wggw/0, createdBy=7ce01621306, createdName=天涯183, createdTime=Sat Feb 11 10:42:39 CST 2017, time=2017-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=175484, encodeId=87c81e5484a0, content=社会现象。, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2017/04/21/72142930668371951a41ef4ea4b233e6.jpg, createdBy=dcbc1715228, createdName=刘煜, createdTime=Sat Feb 11 06:51:37 CST 2017, time=2017-02-11, status=1, ipAttribution=)]

2017-02-13 鼎臣咨询

好文，顶一个

61 0

[GetPortalCommentsPageByObjectIdResponse(id=1666641, encodeId=c03116666413c, content=<a href='/topic/show?id=df6a8e287d7' target=_blank style='color:#2F92EE;'>#药代#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87287, encryptionId=df6a8e287d7, topicName=药代)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bccf26064950, createdName=fengyqf, createdTime=Mon Feb 27 06:49:00 CST 2017, time=2017-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1687269, encodeId=4a8e168e269e3, content=<a href='/topic/show?id=df72966659b' target=_blank style='color:#2F92EE;'>#销售#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96665, encryptionId=df72966659b, topicName=销售)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bca28361924, createdName=1249862am81(暂无昵称), createdTime=Fri Nov 03 10:49:00 CST 2017, time=2017-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=175898, encodeId=7a2e1e5898bc, content=好文，顶一个, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9692001322, createdName=鼎臣咨询, createdTime=Mon Feb 13 11:33:29 CST 2017, time=2017-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1408823, encodeId=8bea1408823e5, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Sun Feb 12 07:49:00 CST 2017, time=2017-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1443574, encodeId=0d7d14435e489, content=<a href='/topic/show?id=eaf6352e26e' target=_blank style='color:#2F92EE;'>#医药代表#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35272, encryptionId=eaf6352e26e, topicName=医药代表)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKUnmV4MWxxicaHm4w2E4EPicofrVHWChQPKibnOtt8t8j7jYGkdKxNvF0KkC2sDXw04QS2GS2UUBSLg/132, createdBy=5cc15086507, createdName=ms9203727104890838, createdTime=Sun Feb 12 07:49:00 CST 2017, time=2017-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590897, encodeId=7b7c159089e63, content=<a href='/topic/show?id=f175424e6fe' target=_blank style='color:#2F92EE;'>#备案#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42476, encryptionId=f175424e6fe, topicName=备案)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=41f217885803, createdName=cenghis, createdTime=Sun Feb 12 07:49:00 CST 2017, time=2017-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=175605, encodeId=90f11e560557, content=能执行吗, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20170206/IMG589879E392F941842.jpg, createdBy=f4d469996, createdName=wangyunyb, createdTime=Sat Feb 11 16:38:37 CST 2017, time=2017-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=175566, encodeId=643c1e5566d6, content=真的吗？, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6d551998554, createdName=1e1c07bdm01(暂无匿称), createdTime=Sat Feb 11 11:33:30 CST 2017, time=2017-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=175550, encodeId=7f621e55508b, content=非常大的改革, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7LIiaRZTzJ3SEfiauCzTMPW7YvPPYLNJBXG9oh6Al1icq2VQQkIHWxqXehcicTS62YKJVBhxeth3wggw/0, createdBy=7ce01621306, createdName=天涯183, createdTime=Sat Feb 11 10:42:39 CST 2017, time=2017-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=175484, encodeId=87c81e5484a0, content=社会现象。, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2017/04/21/72142930668371951a41ef4ea4b233e6.jpg, createdBy=dcbc1715228, createdName=刘煜, createdTime=Sat Feb 11 06:51:37 CST 2017, time=2017-02-11, status=1, ipAttribution=)]

2017-02-12 cathymary

#医药#

33 0

[GetPortalCommentsPageByObjectIdResponse(id=1666641, encodeId=c03116666413c, content=<a href='/topic/show?id=df6a8e287d7' target=_blank style='color:#2F92EE;'>#药代#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87287, encryptionId=df6a8e287d7, topicName=药代)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bccf26064950, createdName=fengyqf, createdTime=Mon Feb 27 06:49:00 CST 2017, time=2017-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1687269, encodeId=4a8e168e269e3, content=<a href='/topic/show?id=df72966659b' target=_blank style='color:#2F92EE;'>#销售#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96665, encryptionId=df72966659b, topicName=销售)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bca28361924, createdName=1249862am81(暂无昵称), createdTime=Fri Nov 03 10:49:00 CST 2017, time=2017-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=175898, encodeId=7a2e1e5898bc, content=好文，顶一个, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9692001322, createdName=鼎臣咨询, createdTime=Mon Feb 13 11:33:29 CST 2017, time=2017-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1408823, encodeId=8bea1408823e5, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Sun Feb 12 07:49:00 CST 2017, time=2017-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1443574, encodeId=0d7d14435e489, content=<a href='/topic/show?id=eaf6352e26e' target=_blank style='color:#2F92EE;'>#医药代表#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35272, encryptionId=eaf6352e26e, topicName=医药代表)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKUnmV4MWxxicaHm4w2E4EPicofrVHWChQPKibnOtt8t8j7jYGkdKxNvF0KkC2sDXw04QS2GS2UUBSLg/132, createdBy=5cc15086507, createdName=ms9203727104890838, createdTime=Sun Feb 12 07:49:00 CST 2017, time=2017-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590897, encodeId=7b7c159089e63, content=<a href='/topic/show?id=f175424e6fe' target=_blank style='color:#2F92EE;'>#备案#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42476, encryptionId=f175424e6fe, topicName=备案)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=41f217885803, createdName=cenghis, createdTime=Sun Feb 12 07:49:00 CST 2017, time=2017-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=175605, encodeId=90f11e560557, content=能执行吗, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20170206/IMG589879E392F941842.jpg, createdBy=f4d469996, createdName=wangyunyb, createdTime=Sat Feb 11 16:38:37 CST 2017, time=2017-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=175566, encodeId=643c1e5566d6, content=真的吗？, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6d551998554, createdName=1e1c07bdm01(暂无匿称), createdTime=Sat Feb 11 11:33:30 CST 2017, time=2017-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=175550, encodeId=7f621e55508b, content=非常大的改革, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7LIiaRZTzJ3SEfiauCzTMPW7YvPPYLNJBXG9oh6Al1icq2VQQkIHWxqXehcicTS62YKJVBhxeth3wggw/0, createdBy=7ce01621306, createdName=天涯183, createdTime=Sat Feb 11 10:42:39 CST 2017, time=2017-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=175484, encodeId=87c81e5484a0, content=社会现象。, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2017/04/21/72142930668371951a41ef4ea4b233e6.jpg, createdBy=dcbc1715228, createdName=刘煜, createdTime=Sat Feb 11 06:51:37 CST 2017, time=2017-02-11, status=1, ipAttribution=)]

2017-02-12 ms9203727104890838

#医药代表#

34 0

[GetPortalCommentsPageByObjectIdResponse(id=1666641, encodeId=c03116666413c, content=<a href='/topic/show?id=df6a8e287d7' target=_blank style='color:#2F92EE;'>#药代#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87287, encryptionId=df6a8e287d7, topicName=药代)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bccf26064950, createdName=fengyqf, createdTime=Mon Feb 27 06:49:00 CST 2017, time=2017-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1687269, encodeId=4a8e168e269e3, content=<a href='/topic/show?id=df72966659b' target=_blank style='color:#2F92EE;'>#销售#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96665, encryptionId=df72966659b, topicName=销售)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bca28361924, createdName=1249862am81(暂无昵称), createdTime=Fri Nov 03 10:49:00 CST 2017, time=2017-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=175898, encodeId=7a2e1e5898bc, content=好文，顶一个, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9692001322, createdName=鼎臣咨询, createdTime=Mon Feb 13 11:33:29 CST 2017, time=2017-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1408823, encodeId=8bea1408823e5, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Sun Feb 12 07:49:00 CST 2017, time=2017-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1443574, encodeId=0d7d14435e489, content=<a href='/topic/show?id=eaf6352e26e' target=_blank style='color:#2F92EE;'>#医药代表#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35272, encryptionId=eaf6352e26e, topicName=医药代表)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKUnmV4MWxxicaHm4w2E4EPicofrVHWChQPKibnOtt8t8j7jYGkdKxNvF0KkC2sDXw04QS2GS2UUBSLg/132, createdBy=5cc15086507, createdName=ms9203727104890838, createdTime=Sun Feb 12 07:49:00 CST 2017, time=2017-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590897, encodeId=7b7c159089e63, content=<a href='/topic/show?id=f175424e6fe' target=_blank style='color:#2F92EE;'>#备案#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42476, encryptionId=f175424e6fe, topicName=备案)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=41f217885803, createdName=cenghis, createdTime=Sun Feb 12 07:49:00 CST 2017, time=2017-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=175605, encodeId=90f11e560557, content=能执行吗, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20170206/IMG589879E392F941842.jpg, createdBy=f4d469996, createdName=wangyunyb, createdTime=Sat Feb 11 16:38:37 CST 2017, time=2017-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=175566, encodeId=643c1e5566d6, content=真的吗？, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6d551998554, createdName=1e1c07bdm01(暂无匿称), createdTime=Sat Feb 11 11:33:30 CST 2017, time=2017-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=175550, encodeId=7f621e55508b, content=非常大的改革, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7LIiaRZTzJ3SEfiauCzTMPW7YvPPYLNJBXG9oh6Al1icq2VQQkIHWxqXehcicTS62YKJVBhxeth3wggw/0, createdBy=7ce01621306, createdName=天涯183, createdTime=Sat Feb 11 10:42:39 CST 2017, time=2017-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=175484, encodeId=87c81e5484a0, content=社会现象。, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2017/04/21/72142930668371951a41ef4ea4b233e6.jpg, createdBy=dcbc1715228, createdName=刘煜, createdTime=Sat Feb 11 06:51:37 CST 2017, time=2017-02-11, status=1, ipAttribution=)]

2017-02-12 cenghis

#备案#

40 0

[GetPortalCommentsPageByObjectIdResponse(id=1666641, encodeId=c03116666413c, content=<a href='/topic/show?id=df6a8e287d7' target=_blank style='color:#2F92EE;'>#药代#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87287, encryptionId=df6a8e287d7, topicName=药代)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bccf26064950, createdName=fengyqf, createdTime=Mon Feb 27 06:49:00 CST 2017, time=2017-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1687269, encodeId=4a8e168e269e3, content=<a href='/topic/show?id=df72966659b' target=_blank style='color:#2F92EE;'>#销售#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96665, encryptionId=df72966659b, topicName=销售)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bca28361924, createdName=1249862am81(暂无昵称), createdTime=Fri Nov 03 10:49:00 CST 2017, time=2017-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=175898, encodeId=7a2e1e5898bc, content=好文，顶一个, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9692001322, createdName=鼎臣咨询, createdTime=Mon Feb 13 11:33:29 CST 2017, time=2017-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1408823, encodeId=8bea1408823e5, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Sun Feb 12 07:49:00 CST 2017, time=2017-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1443574, encodeId=0d7d14435e489, content=<a href='/topic/show?id=eaf6352e26e' target=_blank style='color:#2F92EE;'>#医药代表#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35272, encryptionId=eaf6352e26e, topicName=医药代表)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKUnmV4MWxxicaHm4w2E4EPicofrVHWChQPKibnOtt8t8j7jYGkdKxNvF0KkC2sDXw04QS2GS2UUBSLg/132, createdBy=5cc15086507, createdName=ms9203727104890838, createdTime=Sun Feb 12 07:49:00 CST 2017, time=2017-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590897, encodeId=7b7c159089e63, content=<a href='/topic/show?id=f175424e6fe' target=_blank style='color:#2F92EE;'>#备案#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42476, encryptionId=f175424e6fe, topicName=备案)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=41f217885803, createdName=cenghis, createdTime=Sun Feb 12 07:49:00 CST 2017, time=2017-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=175605, encodeId=90f11e560557, content=能执行吗, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20170206/IMG589879E392F941842.jpg, createdBy=f4d469996, createdName=wangyunyb, createdTime=Sat Feb 11 16:38:37 CST 2017, time=2017-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=175566, encodeId=643c1e5566d6, content=真的吗？, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6d551998554, createdName=1e1c07bdm01(暂无匿称), createdTime=Sat Feb 11 11:33:30 CST 2017, time=2017-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=175550, encodeId=7f621e55508b, content=非常大的改革, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7LIiaRZTzJ3SEfiauCzTMPW7YvPPYLNJBXG9oh6Al1icq2VQQkIHWxqXehcicTS62YKJVBhxeth3wggw/0, createdBy=7ce01621306, createdName=天涯183, createdTime=Sat Feb 11 10:42:39 CST 2017, time=2017-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=175484, encodeId=87c81e5484a0, content=社会现象。, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2017/04/21/72142930668371951a41ef4ea4b233e6.jpg, createdBy=dcbc1715228, createdName=刘煜, createdTime=Sat Feb 11 06:51:37 CST 2017, time=2017-02-11, status=1, ipAttribution=)]

2017-02-11 wangyunyb

能执行吗

71 0

[GetPortalCommentsPageByObjectIdResponse(id=1666641, encodeId=c03116666413c, content=<a href='/topic/show?id=df6a8e287d7' target=_blank style='color:#2F92EE;'>#药代#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87287, encryptionId=df6a8e287d7, topicName=药代)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bccf26064950, createdName=fengyqf, createdTime=Mon Feb 27 06:49:00 CST 2017, time=2017-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1687269, encodeId=4a8e168e269e3, content=<a href='/topic/show?id=df72966659b' target=_blank style='color:#2F92EE;'>#销售#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96665, encryptionId=df72966659b, topicName=销售)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bca28361924, createdName=1249862am81(暂无昵称), createdTime=Fri Nov 03 10:49:00 CST 2017, time=2017-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=175898, encodeId=7a2e1e5898bc, content=好文，顶一个, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9692001322, createdName=鼎臣咨询, createdTime=Mon Feb 13 11:33:29 CST 2017, time=2017-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1408823, encodeId=8bea1408823e5, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Sun Feb 12 07:49:00 CST 2017, time=2017-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1443574, encodeId=0d7d14435e489, content=<a href='/topic/show?id=eaf6352e26e' target=_blank style='color:#2F92EE;'>#医药代表#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35272, encryptionId=eaf6352e26e, topicName=医药代表)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKUnmV4MWxxicaHm4w2E4EPicofrVHWChQPKibnOtt8t8j7jYGkdKxNvF0KkC2sDXw04QS2GS2UUBSLg/132, createdBy=5cc15086507, createdName=ms9203727104890838, createdTime=Sun Feb 12 07:49:00 CST 2017, time=2017-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590897, encodeId=7b7c159089e63, content=<a href='/topic/show?id=f175424e6fe' target=_blank style='color:#2F92EE;'>#备案#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42476, encryptionId=f175424e6fe, topicName=备案)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=41f217885803, createdName=cenghis, createdTime=Sun Feb 12 07:49:00 CST 2017, time=2017-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=175605, encodeId=90f11e560557, content=能执行吗, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20170206/IMG589879E392F941842.jpg, createdBy=f4d469996, createdName=wangyunyb, createdTime=Sat Feb 11 16:38:37 CST 2017, time=2017-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=175566, encodeId=643c1e5566d6, content=真的吗？, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6d551998554, createdName=1e1c07bdm01(暂无匿称), createdTime=Sat Feb 11 11:33:30 CST 2017, time=2017-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=175550, encodeId=7f621e55508b, content=非常大的改革, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7LIiaRZTzJ3SEfiauCzTMPW7YvPPYLNJBXG9oh6Al1icq2VQQkIHWxqXehcicTS62YKJVBhxeth3wggw/0, createdBy=7ce01621306, createdName=天涯183, createdTime=Sat Feb 11 10:42:39 CST 2017, time=2017-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=175484, encodeId=87c81e5484a0, content=社会现象。, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2017/04/21/72142930668371951a41ef4ea4b233e6.jpg, createdBy=dcbc1715228, createdName=刘煜, createdTime=Sat Feb 11 06:51:37 CST 2017, time=2017-02-11, status=1, ipAttribution=)]

2017-02-11 1e1c07bdm01(暂无匿称)

真的吗？

75 0

[GetPortalCommentsPageByObjectIdResponse(id=1666641, encodeId=c03116666413c, content=<a href='/topic/show?id=df6a8e287d7' target=_blank style='color:#2F92EE;'>#药代#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87287, encryptionId=df6a8e287d7, topicName=药代)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bccf26064950, createdName=fengyqf, createdTime=Mon Feb 27 06:49:00 CST 2017, time=2017-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1687269, encodeId=4a8e168e269e3, content=<a href='/topic/show?id=df72966659b' target=_blank style='color:#2F92EE;'>#销售#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96665, encryptionId=df72966659b, topicName=销售)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bca28361924, createdName=1249862am81(暂无昵称), createdTime=Fri Nov 03 10:49:00 CST 2017, time=2017-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=175898, encodeId=7a2e1e5898bc, content=好文，顶一个, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9692001322, createdName=鼎臣咨询, createdTime=Mon Feb 13 11:33:29 CST 2017, time=2017-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1408823, encodeId=8bea1408823e5, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Sun Feb 12 07:49:00 CST 2017, time=2017-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1443574, encodeId=0d7d14435e489, content=<a href='/topic/show?id=eaf6352e26e' target=_blank style='color:#2F92EE;'>#医药代表#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35272, encryptionId=eaf6352e26e, topicName=医药代表)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKUnmV4MWxxicaHm4w2E4EPicofrVHWChQPKibnOtt8t8j7jYGkdKxNvF0KkC2sDXw04QS2GS2UUBSLg/132, createdBy=5cc15086507, createdName=ms9203727104890838, createdTime=Sun Feb 12 07:49:00 CST 2017, time=2017-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590897, encodeId=7b7c159089e63, content=<a href='/topic/show?id=f175424e6fe' target=_blank style='color:#2F92EE;'>#备案#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42476, encryptionId=f175424e6fe, topicName=备案)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=41f217885803, createdName=cenghis, createdTime=Sun Feb 12 07:49:00 CST 2017, time=2017-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=175605, encodeId=90f11e560557, content=能执行吗, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20170206/IMG589879E392F941842.jpg, createdBy=f4d469996, createdName=wangyunyb, createdTime=Sat Feb 11 16:38:37 CST 2017, time=2017-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=175566, encodeId=643c1e5566d6, content=真的吗？, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6d551998554, createdName=1e1c07bdm01(暂无匿称), createdTime=Sat Feb 11 11:33:30 CST 2017, time=2017-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=175550, encodeId=7f621e55508b, content=非常大的改革, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7LIiaRZTzJ3SEfiauCzTMPW7YvPPYLNJBXG9oh6Al1icq2VQQkIHWxqXehcicTS62YKJVBhxeth3wggw/0, createdBy=7ce01621306, createdName=天涯183, createdTime=Sat Feb 11 10:42:39 CST 2017, time=2017-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=175484, encodeId=87c81e5484a0, content=社会现象。, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2017/04/21/72142930668371951a41ef4ea4b233e6.jpg, createdBy=dcbc1715228, createdName=刘煜, createdTime=Sat Feb 11 06:51:37 CST 2017, time=2017-02-11, status=1, ipAttribution=)]

2017-02-11 天涯183

非常大的改革

54 0

[GetPortalCommentsPageByObjectIdResponse(id=1666641, encodeId=c03116666413c, content=<a href='/topic/show?id=df6a8e287d7' target=_blank style='color:#2F92EE;'>#药代#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87287, encryptionId=df6a8e287d7, topicName=药代)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bccf26064950, createdName=fengyqf, createdTime=Mon Feb 27 06:49:00 CST 2017, time=2017-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1687269, encodeId=4a8e168e269e3, content=<a href='/topic/show?id=df72966659b' target=_blank style='color:#2F92EE;'>#销售#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96665, encryptionId=df72966659b, topicName=销售)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bca28361924, createdName=1249862am81(暂无昵称), createdTime=Fri Nov 03 10:49:00 CST 2017, time=2017-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=175898, encodeId=7a2e1e5898bc, content=好文，顶一个, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9692001322, createdName=鼎臣咨询, createdTime=Mon Feb 13 11:33:29 CST 2017, time=2017-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1408823, encodeId=8bea1408823e5, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Sun Feb 12 07:49:00 CST 2017, time=2017-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1443574, encodeId=0d7d14435e489, content=<a href='/topic/show?id=eaf6352e26e' target=_blank style='color:#2F92EE;'>#医药代表#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35272, encryptionId=eaf6352e26e, topicName=医药代表)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKUnmV4MWxxicaHm4w2E4EPicofrVHWChQPKibnOtt8t8j7jYGkdKxNvF0KkC2sDXw04QS2GS2UUBSLg/132, createdBy=5cc15086507, createdName=ms9203727104890838, createdTime=Sun Feb 12 07:49:00 CST 2017, time=2017-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590897, encodeId=7b7c159089e63, content=<a href='/topic/show?id=f175424e6fe' target=_blank style='color:#2F92EE;'>#备案#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42476, encryptionId=f175424e6fe, topicName=备案)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=41f217885803, createdName=cenghis, createdTime=Sun Feb 12 07:49:00 CST 2017, time=2017-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=175605, encodeId=90f11e560557, content=能执行吗, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20170206/IMG589879E392F941842.jpg, createdBy=f4d469996, createdName=wangyunyb, createdTime=Sat Feb 11 16:38:37 CST 2017, time=2017-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=175566, encodeId=643c1e5566d6, content=真的吗？, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6d551998554, createdName=1e1c07bdm01(暂无匿称), createdTime=Sat Feb 11 11:33:30 CST 2017, time=2017-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=175550, encodeId=7f621e55508b, content=非常大的改革, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7LIiaRZTzJ3SEfiauCzTMPW7YvPPYLNJBXG9oh6Al1icq2VQQkIHWxqXehcicTS62YKJVBhxeth3wggw/0, createdBy=7ce01621306, createdName=天涯183, createdTime=Sat Feb 11 10:42:39 CST 2017, time=2017-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=175484, encodeId=87c81e5484a0, content=社会现象。, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2017/04/21/72142930668371951a41ef4ea4b233e6.jpg, createdBy=dcbc1715228, createdName=刘煜, createdTime=Sat Feb 11 06:51:37 CST 2017, time=2017-02-11, status=1, ipAttribution=)]

2017-02-11 刘煜

社会现象。

61 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

报道

国务院：300万医药代表全部登记备案！不得承担销售任务

相关资讯

科室

工具

服务